Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity.
COVID-19
Post-COVID
Pulmonary function impairment
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
06
2021
accepted:
13
07
2021
pubmed:
30
7
2021
medline:
3
2
2022
entrez:
29
7
2021
Statut:
ppublish
Résumé
Evaluation of pulmonary function impairment after COVID-19 in persistently symptomatic and asymptomatic patients of all disease severities and characterisation of risk factors. Patients with confirmed SARS-CoV-2 infection underwent prospective follow-up with pulmonary function testing and blood gas analysis during steady-state cycle exercise 4 months after acute illness. Pulmonary function impairment (PFI) was defined as reduction below 80% predicted of DLCOcSB, TLC, FVC, or FEV1. Clinical data were analyzed to identify risk factors for impaired pulmonary function. 76 patients were included, hereof 35 outpatients with mild disease and 41 patients hospitalized due to COVID-19. Sixteen patients had critical disease requiring mechanical ventilation, 25 patients had moderate-severe disease. After 4 months, 44 patients reported persisting respiratory symptoms. Significant PFI was prevalent in 40 patients (52.6%) occurring among all disease severities. The most common cause for PFI was reduced DLCOcSB (n = 39, 51.3%), followed by reduced TLC and FVC. The severity of PFI was significantly associated with mechanical ventilation (p < 0.001). Further risk factors for DLCO impairment were COPD (p < 0.001), SARS-CoV-2 antibody-Titer (p = 0.014) and in hospitalized patients CT score. A decrease of paO2 > 3 mmHg during cycle exercise occurred in 1/5 of patients after mild disease course. We characterized pulmonary function impairment in asymptomatic and persistently symptomatic patients of different severity groups of COVID-19 and identified further risk factors associated with persistently decreased pulmonary function. Remarkably, gas exchange abnormalities were revealed upon cycle exercise in some patients with mild disease courses and no preexisting pulmonary condition.
Identifiants
pubmed: 34322859
doi: 10.1007/s15010-021-01669-8
pii: 10.1007/s15010-021-01669-8
pmc: PMC8318328
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-168Informations de copyright
© 2021. The Author(s).
Références
Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.
doi: 10.1056/NEJMoa2001316
Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
doi: 10.1016/S0140-6736(20)30211-7
Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
doi: 10.1001/jama.2020.1585
Jakob CEM, et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” Infection. 2021;49:63–73.
doi: 10.1007/s15010-020-01499-0
Needham DM, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders’ conference. Crit Care Med. 2012;40:502–9.
doi: 10.1097/CCM.0b013e318232da75
Bieber S, et al. Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury. Infection. 2021;49:491–500.
doi: 10.1007/s15010-020-01572-8
Spiro JE, et al. Secondary tension pneumothorax in a COVID-19 pneumonia patient: a case report. Infection. 2020;48:941–4.
doi: 10.1007/s15010-020-01457-w
Weber S, et al. Severe liver failure during SARS-CoV-2 infection. Gut. 2020;69:1365–7.
doi: 10.1136/gutjnl-2020-321350
Tan BK, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021. https://doi.org/10.1136/thoraxjnl-2020-215383 .
doi: 10.1136/thoraxjnl-2020-215383
pubmed: 34580193
Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32.
doi: 10.1016/S0140-6736(20)32656-8
Quanjer PH, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6:5–40.
doi: 10.1183/09041950.005s1693
Quanjer PH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.
doi: 10.1183/09031936.00080312
Coates AL, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49:1601526.
doi: 10.1183/13993003.01526-2016
Munker D, et al. Dynamics of SARS-CoV-2 shedding in the respiratory depends on the severity of disease in COVID-19 patients. Eur Respir J. 2021. https://doi.org/10.1183/13993003.02724-2020 .
doi: 10.1183/13993003.02724-2020
pubmed: 33602859
pmcid: 7898160
Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
Antonio GE, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228:810–5.
doi: 10.1148/radiol.2283030726
Chung M, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295:202–7.
doi: 10.1148/radiol.2020200230
Dai H, et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. Int J Infect Dis. 2020;95:106–12.
doi: 10.1016/j.ijid.2020.04.003
Muenchhoff M, et al. Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020. Euro Surveill. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.24.2001057 .
doi: 10.2807/1560-7917.ES.2020.25.24.2001057
pubmed: 32583765
pmcid: 7427299
Huang Y, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21:163.
doi: 10.1186/s12931-020-01429-6
You J, et al. Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. J Infect. 2020;81:e150–2.
doi: 10.1016/j.jinf.2020.06.003
Anastasio F, et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J. 2021. https://doi.org/10.1183/13993003.04015-2020 .
doi: 10.1183/13993003.04015-2020
pubmed: 33574080
pmcid: 7877327
Torres-Castro R, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2020. https://doi.org/10.1016/j.pulmoe.2020.10.013 .
doi: 10.1016/j.pulmoe.2020.10.013
pubmed: 33262076
pmcid: 7687368
Fumagalli A, et al. Pulmonary function in patients surviving to COVID-19 pneumonia. Infection. 2021;49:153–7.
doi: 10.1007/s15010-020-01474-9
Fortini A, et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021. https://doi.org/10.1007/s15010-021-01638-1 .
doi: 10.1007/s15010-021-01638-1
pubmed: 34091869
pmcid: 8179958
Zou H, Li SQ. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention. Acta Pharmacol Sin. 2020. https://doi.org/10.1038/s41401-020-00566-4 .
doi: 10.1038/s41401-020-00566-4
pubmed: 33303990
pmcid: 7662810
Liu Q, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36:21–3.
pubmed: 32198987
Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–8.
doi: 10.1056/NEJMoa2015432
Hui DS, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–9.
doi: 10.1136/thx.2004.030205
Wells AU, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453–60.
doi: 10.1016/S2213-2600(20)30036-9
Guler SA, et al. Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021. https://doi.org/10.1183/13993003.03690-2020 .
doi: 10.1183/13993003.03690-2020
pubmed: 34140296
pmcid: 8674517
Qu J, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:2255–8.
doi: 10.1093/cid/ciaa489
Zohar T, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183:1508-1519 e12.
doi: 10.1016/j.cell.2020.10.052
Seddiki N, French M. COVID-19 and HIV-associated immune reconstitution inflammatory syndrome: emergence of pathogen-specific immune responses adding fuel to the fire. Front Immunol. 2021;12:649567.
doi: 10.3389/fimmu.2021.649567
Rinaldo RF, et al. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Respir J. 2021. https://doi.org/10.1183/13993003.00870-2021 .
doi: 10.1183/13993003.00870-2021
pubmed: 33926969
pmcid: 8082950
Ostransky D, Blais FX. Postviral bronchial hyperreactivity syndrome: recognizing asthma's great mimic. J Am Osteopath Assoc. 1991;91(5): 465–8, 471–5.
Folkerts G, et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med. 1998;157:1708–20.
doi: 10.1164/ajrccm.157.6.9707163
Lee SC, et al. Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea. Sci Rep. 2021;11:3735.
doi: 10.1038/s41598-021-83226-9
Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129.
doi: 10.1016/S2213-2600(21)00031-X
Zhao YM, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
doi: 10.1016/j.eclinm.2020.100463